-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166

Benzinga·11/04/2026 13:55:05
Diffusion vocale
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $160 to $166.